Alan C. O'COnnor

Alan C. O'COnnor

Auto-generated profile, based on publicly available information

Alan C. O'COnnor

RTI International

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2018 in The Journal of Technology Transfer
Verified
Journal Article
Closed access
PDF file
CHChristopher S. Hayter
Christopher S. Hayter
ANAndrew J. Nelson
Andrew J. Nelson
SZStephanie Zayed
Stephanie Zayed
AOAlan C. O’connor
Alan C. O’connor

27 March 2014 in Annals of the New York Academy of Sciences
Verified
Journal Article
Open access
PDF file
TSTroy J. Scott
Troy J. Scott
AOAlan C. O'COnnor
Alan C. O'COnnor
ALAlbert N. Link
Albert N. Link
TBTravis J. Beaulieu
Travis J. Beaulieu
The development of disease‐modifying treatments for Alzheimer's disease (AD) faces a number of barriers. Among these are the lack of surrogate biomarkers, the exceptional size and duration of clinical trials, difficulties in identifying appropriate populations for clinical trials, and the limitations of monotherapies in addressing such a complex multifactorial disease. This study sets out to first estimate the consequent impact on the expected cost of developing disease‐modifying treatments for AD and then to estimate the potential benefits of bringing together industry, academic, and government stakeholders to co‐invest in, for example, developing better biomarkers and cognitive assessment tools, building out advanced registries and clinical trial‐readiness cohorts, and establishing clinical trial platforms to investigate combinations of candidate drugs and biomarkers from the portfolios of multiple companies. Estimates based on interviews with experts on AD research and development suggest that the cost of one new drug is now $5.7 billion (95% confidence interval (CI) $3.7–9.5 billion) and could be reduced to $2.0 billion (95% CI $1.5–2.9 billion). The associated acceleration in the arrival of disease‐modifying treatments could reduce the number of case years of dementia by 7.0 million (95% CI 4.4–9.4 million) in the United States from 2025 through 2040.

1 June 2013 in Vaccine
Verified
Journal Article
Closed access
AOAlan C. O’cOnnor
Alan C. O’cOnnor
EKErin D. Kennedy
Erin D. Kennedy
RLRoss J. Loomis
Ross J. Loomis
SHSaira N. Haque
Saira N. Haque
CLChristine M. Layton
Christine M. Layton
CWCindy Weinbaum
Cindy Weinbaum

22 November 2021 in Journal of Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
BABenjamin J. Anderson
Benjamin J. Anderson
OLOlena Leonchuk
Olena Leonchuk
AOAlan C. O’cOnnor
Alan C. O’cOnnor
BSBrooke K. Shaw
Brooke K. Shaw
AWAmanda C. Walsh
Amanda C. Walsh
Background: The National Institutes of Health launched the NIH Centers for Accelerated Innovation and the Research Evaluation and Commercialization Hubs programs to develop approaches and strategies to promote academic entrepreneurship and translate research discoveries into products and tools to help patients. The two programs collectively funded 11 sites at individual research institutions or consortia of institutions around the United States. Sites provided funding, project management, and coaching to funded investigators and commercialization education programs open to their research communities. Methods: We implemented an evaluation program that included longitudinal tracking of funded technology development projects and commercialization outcomes; interviews with site teams, funded investigators, and relevant institutional and innovation ecosystem stakeholders and analysis and review of administrative data. Results: As of May 2021, interim results for 366 funded projects show that technologies have received nearly $1.7 billion in follow-on funding to-date. There were 88 start-ups formed, a 40% Small Business Innovation Research/Small Business Technology Transfer application success rate, and 17 licenses with small and large businesses. Twelve technologies are currently in clinical testing and three are on the market. Conclusions: Best practices used by the sites included leadership teams using milestone-based project management, external advisory boards that evaluated funding applications for commercial merit as well as scientific, sustained engagement with the academic community about commercialization in an effort to shift attitudes about commercialization, application processes synced with education programs, and the provision of project managers with private-sector product development expertise to coach funded investigators.

27 April 2022 in Small Business Economics
Verified
Journal Article
Closed access
PDF file
JFJoshua C. R. Fletcher
Joshua C. R. Fletcher
EHEric S. Howard
Eric S. Howard
ALAlbert N. Link
Albert N. Link
AOAlan C. O’cOnnor
Alan C. O’cOnnor

1 August 2010
Verified
Report
Closed access
PDF file
AOAlan C. O'COnnor
Alan C. O'COnnor
RLRoss J. Loomis
Ross J. Loomis
FBFern M. Braun
Fern M. Braun
The U.S. Department of Energy's Office of Scientific and Technical Information